Abstract 85P
Background
Treatment recommendations and benefit of local therapy in oligometastatic disease (OMD) are an era of interest and debate; however, it’s quite difficult to plan RCTs including patients with metastases due to ethical considerations as patients may lose an effective treatment if they are assigned to a control arm, furthermore, most of the clinical literature on OMD is cancer site specific, this study included OMD of different solid tumors.
Methods
In this observational prospective cohort study Patients with stage IV solid tumors who met the criteria of OMD (≤5 metastatic lesions, and or ≤2 organs) with performance status 0-2 were eligible; we studied disease characteristics and outcomes regarding local therapies of OMD.
Results
Two hundred and thirty-four patients with solid tumors met the criteria of OMD, 126 (53.8%) Patients received local therapies; surgery, Radiotherapy (RT), local ablative therapy (group I) and 108 (46.2%) Patients didn’t receive local therapy (group II). Comparing both groups, Group I: patients had significantly younger age, earlier initial TNM stage, higher rates of metachronous onset, symptomatic disease, soft tissue disease, single lesion and or single organ involvement and complete response, but lower rates of managed pulmonary OMD compared to group II. However, no significant association with specific primary cancer site, histological grade, molecular subtype, SUV activity level in PET/CT, type and number of systemic therapy lines, type of OMD (genuine vs. induced and repeated vs. de novo), cut of point of serum tumor markers or any subsequent delay of systemic treatment were noticed with local therapy (p value >0.05) and unexpectedly metastatic size of ≥ 3 cm was more amenable for local therapy (p value ≤0.05). Regarding survival, local therapy of OMD was associated with better PFS and OS: The mean OS in local therapy group was 64 months vs. 38 months in non local therapy patients and the median PFS was not reached in local therapy patients vs. 30 months in no local therapy patients. By multivariate regression analysis; local therapy for OMD is an independent prognostic factor for both PFS and OS.
Conclusions
For selected oligometastatic solid tumor patients, local therapy for OMD could improve PFS and OS.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Menoufia University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
426P - Characterization of a novel comprehensive genomic profiling test with better detection of heterozygous deletions and gene fusions
Presenter: ryouta kakuta
Session: Poster Display
Resources:
Abstract
427P - Real-world performance of a comprehensive next-generation sequencing (NGS) panel for patients (pts) with solid tumors from Asia and the Middle East (AME)
Presenter: Nitesh Rohatgi
Session: Poster Display
Resources:
Abstract
428P - What do women want to see in a personalized breast cancer risk report? A qualitative study of Asian women of two countries
Presenter: Faustina Audrey Agatha
Session: Poster Display
Resources:
Abstract
429P - Clinical utility and outcomes of liquid biopsy-based next generation sequencing in identification of actionable genomic mutations in solid malignancy: A single center retrospective study in the Philippines
Presenter: Omar Maaño
Session: Poster Display
Resources:
Abstract
436P - Chemotherapy-induced hand-foot syndrome, comparative efficacy and safety of pharmacological prophylaxis: Systematic review and network meta-analysis
Presenter: Anand Srinivasan
Session: Poster Display
Resources:
Abstract
437P - A randomized single blinded phase II trial comparing efficacy and quality of life of topical aloe vera gel plus urea cream versus urea cream alone for prevention of hand-foot syndrome in cancer patients receiving capecitabine
Presenter: Lucksika Wanichtanom
Session: Poster Display
Resources:
Abstract
438P - A novel treatment for immune checkpoint inhibitor-related myocarditis
Presenter: Takahiro Niimura
Session: Poster Display
Resources:
Abstract
439P - Randomized controlled trial evaluating efficacy of topical urea-based cream for capecitabine-associated hand-foot syndrome prevention
Presenter: Concord Wongkraisri
Session: Poster Display
Resources:
Abstract
440P - Real-world adverse events of targeted therapy reported by pharmacist in oncology clinic
Presenter: TIKUMPORN PORNWISETSIRIKUL
Session: Poster Display
Resources:
Abstract
441P - The prophylactic efficacy of telpegfilgrastim, a Y-shape branched pegylated G-CSF in patient with chemotherapy-induced neutropenia: A multicenter, randomized phase III study
Presenter: Xinshuai Wang
Session: Poster Display
Resources:
Abstract